Related Experiment Video
Updated: Jan 4, 2026
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
Angela Botticella1, Laura Mezquita2, Cecile Le Pechoux1
1Department of Radiation Oncology, Gustave Roussy, Villejuif, France.
Abstract:
Stage III non-small cell lung cancer (NSCLC) has a dismal prognosis, with only 15-20% of patients alive at 5 years after concomitant chemo-radiotherapy, which represents the standard treatment. Targeting immune-checkpoint inhibitors represents a standard option for advanced NSCLC. Improvements in understanding of the immune profile of NSCLC has led to the development of immunotherapeutic strategies, including inhibitory molecules responsible for abrogating an anticancer immune response such as programmed cell-death 1 and programmed cell-death ligand 1. A recently published phase III trial (PACIFIC) showed for the first time an improved overall survival in stage III NSCLC patients with consolidative durvalumab. The aim of this review is to summarize and discuss the clinical evidence for the use of durvalumab in stage III NSCLC, with a brief overview on future perspectives in this setting.
Insights
Consolidating stage III non-small cell lung cancer (NSCLC) treatment with durvalumab after chemoradiotherapy significantly improves overall survival. This immunotherapy approach offers new hope for patients with advanced NSCLC.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Trials
Background:
- Stage III non-small cell lung cancer (NSCLC) has a poor prognosis with standard chemoradiotherapy.
- Immune-checkpoint inhibitors targeting PD-1/PD-L1 are established for advanced NSCLC.
- Understanding NSCLC immune profiles drives novel immunotherapeutic strategies.
Purpose of the Study:
- To review clinical evidence for durvalumab in stage III NSCLC.
- To discuss the impact of consolidative durvalumab on overall survival.
- To provide future perspectives for durvalumab in this patient population.
Main Methods:
- Review of clinical evidence, focusing on the PACIFIC phase III trial.
- Analysis of overall survival data for stage III NSCLC patients.
- Discussion of immunotherapy mechanisms in NSCLC.
Main Results:
- The PACIFIC trial demonstrated improved overall survival with consolidative durvalumab.
- Durvalumab represents a significant advancement over standard chemoradiotherapy.
- Targeting PD-1/PD-L1 pathways shows efficacy in NSCLC.
Conclusions:
- Consolidative durvalumab is a new standard of care for stage III NSCLC.
- Immunotherapy with durvalumab offers improved survival outcomes.
- Further research into durvalumab's role in NSCLC is warranted.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
